October 2013

Levomilnacipran (Fetzima): One More SNRI
Levomilnacipran (Fetzima), the newest serotonin-norepinephrine reuptake inhibitor (SNRI), appears superior to placebo in reducing depression symptoms.

Quetiapine in Adolescents with Schizophrenia
In one study, a lower dose (400 mg/day) of quetiapine (Seroquel and others) was as efficacious as a higher dose (800 mg/day) for treating schizophrenia in adolescents.

SSRIs and the Metabolic Syndrome
Some selective serotonin reuptake inhibitor (SSRI) antidepressants appear to increase the risk of the metabolic syndrome, while others do not.

In Brief
ACE Inhibitors May Slow Rate of Cognitive Decline in Patients with Dementia; Risk of Bipolar Disorder and Schizophrenia Is Higher in Relatives of Patients with ADHD

After ECT
Patients who respond to treatment with electroconvulsive therapy (ECT) should receive vigorous maintenance therapy, but there is as yet no expert consensus as to what that therapy should be.

SSRIs and the Metabolic Syndrome

October 2013

Short-term treatment with selective serotonin reuptake inhibitors (SSRIs) often leads to weight loss. However, long-term treatment with some SSRIs—especially paroxetine (Paxil and others)—can cause weight gain.1

Obesity has been increasing in the general…

To view the rest of this article, please: